Transfers, Facilitated and Rescue PCI for AMI Michael J Cowley, M.D., FSCAI Nothing to disclose.

Slides:



Advertisements
Similar presentations
Patient Oriented Therapy for STE-MI
Advertisements

STREAM 1Y AHA 2013 P Sinnaeve STREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION.
GUSTO-IV AMI G lobal U se of S trategies T o Open O ccluded Coronary Arteries in AMI.
Facilitated PCI & rescue PCI Dolly mathew. Primary PCI is the preferred reperfusion strategy in STEMI Most patients donot arrive at the PCI center within.
Presented by: Fahim H. Jafary, M.D., F.A.C.C. Associate Professor of Medicine Aga Khan University Hospital, Karachi March 14, 2008 Primary Percutaneous.
Immediate angioplasty compared to ischemia-guided management after thrombolysis for ST-elevation myocardial infarction in areas with very long transfers.
A Pharmaco-invasive Reperfusion Strategy with Immediate Percutaneous Coronary Intervention is Safe and Effective in ST-Elevation Myocardial Infarction.
Regional AMI Care: Bridging the Rural Health Care Gap Darren B. Bean, MD University of Wisconsin Emergency Medicine/Medflight Director UW Level 1 Heart.
Optimal Timing of PCI in ACS Patrick Hildbrand. Trends and Prognosis in ACS Furman MI, JACC 2001, 37: Hospital 1 year.
Howard C. Herrmann, MD Professor of Medicine Director, Interventional Cardiology and Cardiac Catheterization Laboratories University of Pennsylvania Medical.
Regional Systems of Care to Optimize Timeliness of Reperfusion Therapy for STEMI: The Mayo Clinic Protocol Henry H. Ting, MD, MBA Associate Professor of.
Utilization of Rescue and Facilitated Angioplasty for Primary PCI: Who Should Get Lytic Therapy in 2009? Adnan Kastrati Deutsches Herzzentrum, Technische.
Treatmant patients with acute myocardial infarcton in Bosnia and Herzegovina BH Heart Centre Tuzla Terzić I, Čaluk J, Delić A, Osmanović E, Porović E,
Relationship of Time to Treatment and Door-to-Balloon Time to Mortality in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty Christopher.
Current and Future Perspectives on Acute Coronary Syndromes Paul W. Armstrong MD AMI Quebec Montreal October 1, 2010.
STEMI: What’s the Rush? STEMI: What’s the Rush? William Phillips, MD, FACC, FSCAI Director of Cardiology CMMC A PCI Center perspective.
9803mo01, 1 Trial of Routine ANgioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction The TRANSFER-AMI trial Warren.
Primary PCI Treatment of choice for Acute MI.
Time Is Myocardium and the Wavefront of Necrosis CM Gibson 2002.
GUSTO I GUSTO I Median Time (hrs) Between Symptom Onset and Treatment GUSTO III GUSTO III InTIME II InTIME II ASSENT.
Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,
GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
ACS and Thrombosis in the Emergency Setting
MD DM DNB FACC FICC FCSI FESC LAKSHMI HOSPITAL, PALAKKAD.
Advanced Cardiovascular Intervention 2009 Timings in PPCI: Have we learnt the lessons from our European Colleagues? Peter F Ludman.
A modern thrombolysis service is superior to primary angioplasty
A H Gershlick University Hospital of Leicester UK A H Gershlick University Hospital of Leicester UK AA 2008 Who should we rescue ?
Role of Percutaneous coronary intervention (PCI) after thrombolytic therapy By Dr. Mohamed Mahros Assistant lecturer of cardiology Benha faculty of medicine.
Primary Angioplasty – The case is not proven: pre-hospital thrombolysis with mandated PCI may be equally effective Primary Angioplasty – The case is not.
Management Of AMI Does time matter?? What is the best strategy: PPCI Vs TT.
To Transfer or Not to Transfer? The debate between transfer for PCI versus local thrombolysis. Todd Ring, BSc., MD, CCFP March 11, 2004 University of Calgary.
Patient Transfer Mark de Belder The James Cook University Hospital Middlesbrough.
F. Van de Werf, ACC 2013 STREAM STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION.
National AMI Information Call February 5, 2008 Patient Safety Initiative.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
Myocardial Ischaemia National Audit Project Are we replacing good fibrinolytic treatment with poor primary PCI? John Birkhead who has NO CONFLICT OF INTEREST.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Advanced Angioplasty 2005 Primary PCI making it happen Data collection and Timings Peter Ludman University Hospital Birmingham.
Rescue Angioplasty versus Conservative Therapy or Repeat Thrombolysis Trial Presented at American Heart Association Scientific Sessions 2004 Presented.
Lysis and Beyond: ESC Guidelines and Reality J N Townend Queen Elizabeth Hospital Birmingham.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
UNIVERSITÄT LEIPZIG H E R Z Z E N T R U M Infarct transmurality and infarct size assessed by delayed enhancement magnetic resonance imaging: Association.
West Hertfordshire Primary Angioplasty Service Masood Khan.
1 Advanced Angioplasty London, England 27 January, 2006 Jörg Michael Rustige,MD Medical Director Lilly Critical Care Europe, Geneva.
Inter-Hospital Transfer of High Risk STEMI Patients for PCI is Safe and Feasible David M. Larson, Katie M. Menssen, Scott W. Sharkey, Marc C. Newell, Anil.
Enoxaparin in primary PCI From FINESSE to ATOLL G. Montalescot Institut de Cardiologie Pitié-Salpêtrière Hospital Paris, France The FINESSE Trial is supported.
Door to Balloon Time: Does it Matter? Tale of Two Studies.
Agrément FMC N° Conflits d’intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier, CRAM, AFSSAPS, ARH Région de Bourgogne Clos.
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2007 Focused Update of the ACC/AHA 2004 Guidelines.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
Heart Alert Quandary Kiran K. Cheruku, MD Interventional Cardiologist Heart And Vascular Institute of Texas.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Is the Debate Over? Routine Thrombus Aspiration in STEMI (From TAPAS to INFUSE-AMI to TASTE to TOTAL) Stefan James Professor of Cardiology Uppsala Clinical.
CRT 2015 Unmet Needs in STEMI Interventions
Dartmouth Hitchcock Medical Center
ASSENT-3 PLUS 1,639 patients with STEMI Treatment Group A
Presenter Disclosure Information
Radial vs Femoral Access in ACS Patients
Singapore’s Experience in Primary PCI in the Last Ten Years
STEMI-INITIAL PRESENTATION TIMING 2013 ACC/AHA GUIDELINES
European Society of Cardiology 2003
Published in the European Heart Journal
Global Registry of Acute Coronary Events: GRACE
Circulation 2001;104: Circulation 2001;104:
Management of AMI in patients presenting with STEMI
16-year follow-up of the DANish Acute Myocardial Infarction 2 (DANAMI-2) trial PG Thranea, SD Kristensena, KKW Olesena, LS Mortensenb, HE Bøtkera, L.
Presentation transcript:

Transfers, Facilitated and Rescue PCI for AMI Michael J Cowley, M.D., FSCAI Nothing to disclose

Primary PCI vs Lysis for STEMI Meta-analysis of 23 trials Keeley EC Lancet 2003; 361: p= p< p= p< p< Short Term Events %

Transfer for PCI is better than Lysis! (In a timely manner)

Lysis vs Transport for PCI Meta-analysis of 5 RCT Keeley EC Lancet 2003; 361: p=0.057 p< p<0.05 p=0.25 p< % Average transfer time = 39 min

Transfer for Primary PCI vs Lysis Death, Re-MI, Stroke Dalby M et al: Circ; 2003; 108: 1809 Maastricht PRAGUE Air-Pami CAPTIM DANAMI 2 PRAGUE 2 8/75 14/75 8/101 23/99 6/71 9/66 26/421 34/419 63/ /782 36/429 64/ / /1863 Total OR: 0.58 p< Relative Risk PCI Lysis

DANAMI-2 Primary Endpoint (Death, re-MI, CVA) % Days 14.2% 8.5% NNT= Average transfer time = 68 min

Time Delay Is Important with Primary PCI

Transfers, Facilitated and Rescue PCI Primary PCI is the preferred reperfusion strategy for STEMI if it can be done in a timely manner Only 25% of US hospitals are capable of Primary PCI 82% of STEMI pts transferred from non-PCI hospitals for Primary PCI have Door to Balloon times > 120 min (ACC/NCDR ) Chakrabarti, JACC 2008 Primary PCI is the preferred reperfusion strategy for STEMI if it can be done in a timely manner Only 25% of US hospitals are capable of Primary PCI 82% of STEMI pts transferred from non-PCI hospitals for Primary PCI have Door to Balloon times > 120 min (ACC/NCDR ) Chakrabarti, JACC 2008 Delays due to Long Transfer Times are common

Primary PCI: Access in US Nallamothu et al: Circulation 2006;113:1189 * Weather permitting Pre-Hospital Time Period < 60 min > 60 min 42% PCI hospital is closest facility 79% within 60 min prehospital time*

# of Pts 2,230 5,734 6,616 4,461 2,627 5,412 Cannon CP, et al: JAMA 2000;283:2941–2947 p=0.35 p=0.29 p=0.01 p<0.001 p<0.001 Time (min) Relation Between D2B Times and In-Hospital Mortality in NRMI Multivariate Odds Ratio

Treatment Delays with 1° PCI Brodie B, et al: JACC 2006;47: – 90– 80– 70– 60– 50– Cardiac Survival Door–to–Balloon Time 0 – 1.4 hr 1.5 – 1.9 hr 2.0 – 2.9 hr ≥ 3.0 hr p< Years n = 2,300 % – – – – – – – – – – – 0-90 min min min 180 min

% Transfer for Primary PCI Chakrabarti A: J Am Coll Cardiol 51:2442, 2008 Total door-to-balloon time (hrs) Only 36% <120 min

% Door-In Door-Out Time at Referring Hospital Ting HH: AHA 2009 (abstract) Door-in Door-Out time (min) Median DIDO (IQR) = 74 min (45-132) 40% had DIDO >90 min

p=0.01 Interhospital Delay in Transfer Door-to-Door Times 1 year Mortality (n=616 pts) % De Luca G: AJC 2005; 95: 1361

US Transfer Delay for Primary PCI (NRMI 3 / 4) % Nallamothu B: Circulation 2005; 111: 761 Total Door to Balloon Time (h) <16% < 2h52% > 3h

Rescue PCI

Rescue PCI is better than Lysis!

RESCUE PCI: REACT Trial REACT= Rescue Angioplasty versus Conservative Treatment or Repeat Thrombolysis Gershlick AH, et al: NEJM 2005; 353: Days After Randomization Probability of Event-Free Survival Rescue PCI Conservative Repeat Lysis p= % 70.1% 68.7% Primary End Point (D, re-MI, severe CHF, CVA) at 6 mo

JACC 2007; 49:

% Meta-analysis of 3 RCT (n=700 pts) Wijeysundera HC: JACC 2007; 49: Rescue PCI vs Conservative Rx p=0.09 p=0.04 p=0.04 p=0.05 p=0.001

“Facilitated” PCI

Facilitated PCI Was inferior to pPCI with short transfer times Was harmful in ASSENT 4 Study had serious design flaws Did not address key question: Best Rx for pts with long transfer delays? Was inferior to pPCI with short transfer times Was harmful in ASSENT 4 Study had serious design flaws Did not address key question: Best Rx for pts with long transfer delays?

Reperfusion Options for Transfer Patients with Expected Delays Primary PCI (no matter how long it takes) Lysis; ischemia-guided transfer for rescue PCI Lysis with transfer for immediate (“early” PCI): Pharmaco-invasive strategy Primary PCI (no matter how long it takes) Lysis; ischemia-guided transfer for rescue PCI Lysis with transfer for immediate (“early” PCI): Pharmaco-invasive strategy

Facilitated or Pharmaco-invasive AMICO Registry CARESS-in-AMI TRANSFER-AMI NOR-DISTEMI AMICO Registry CARESS-in-AMI TRANSFER-AMI NOR-DISTEMI

AMICO: Alliance for Myocardial Infarction Care Optimization R McKay A Denktas, H Athar, S Sdringola, Vernon Anderson, R Smalling Timothy Henry, David Larson M Simons, N Niles H Thiele, G Schuler C Ahn, PhD

p=0.002 AMICO Registry: Pharmacoinvasive Rx 30 day Outcomes Henry T, et al: JACC 2008; 1: % p=NS p= p<0.0001

Early Invasive vs Ischemia-guided Rx after Lysis for STEMI: Meta-analysis Wijeysundera HC: AHJ 2008; 156:

% Borgia F: EHJ 2010; 31: Early Routine PCI vs Standard Rx after Lysis p=ns 7 RCT (n=2961 pts) p=0.001 p=0.004 p=0.003 p=0.51 * Rescue PCI: 20% 30 Day Clinical Outcomes

CARESS in AMI: Design UFH (7 U/Kg/h) for transfer PCI: ACT adjusted to ” ;UFH stopped after PCI UFH (7 U/Kg/h) for transfer PCI: ACT adjusted to ” ;UFH stopped after PCI Reteplase UFH bolus (max IV at 7 U/kg/h) Abciximab bolus + IV ASA mg iv Reteplase UFH bolus (max IV at 7 U/kg/h) Abciximab bolus + IV ASA mg iv UFH (7 U/Kg/h for 24 hrs) If Rescue PCI: ACT adjust to ”; UFH stopped after PCI Facilitated PCIMedical Treatment/ Rescue Clopidogrel for 1-12 mo after stenting (514 pts; 82%)

Primary Outcome at 30 days 4.1% 11.1% Death, re-MI, refractory ischaemia OR 0.34 (95%CI ) p=0.001 ‘Facilitated’ CARESS IN AMI DiMario C: Lancet 2008; 371: RescueRescue

PCI Centre Cath Lab CommunityHospitalEmergencyDepartment Cath / PCI < 6 hrs (+ reperfusion) Cath + Rescue PCI  GPI TNK + ASA + UFH / Enoxaparin + Clopidogrel “Pharmacoinvasive Strategy” Urgent Transfer to PCI Centre Assess chest pain, ST  resolution at min after Rx ‘High Risk’ STEMI < 12 hrs Failed Reperfusion* Successful Reperfusion Elective Cath  PCI > 24 hrs later “Standard Treatment” * ST segment resolution < 50% & persistent chest pain, or hemodynamic instability Repatriation of stable pts within 24 hrs of PCI Randomization stratified by age (≤75 vs > 75) and by enrolling site Transfer-AMI

Days from Randomization % Standard (n=496) Pharmacoinvasive (n=508) Pharmacoinvasive vs Lysis for high risk STEMI OR=0.54 (0.37, 0.78) p= N=1,004 pts *Primary EP: Death, re-MI, CHF, Severe re-Ischemia, Shock Primary Endpoint* at 30 Days

PCI in STEMI* CO R LOE Non-Primary PCI (Delayed PCI) Evidence of lytic failure or IRA reocclusionIIaB Patent IRA h after lytic therapyIIaB GNL 2011 *Systems goal for primary PCI: < 90 min of first medical contact at hospital with PCI capability (Class I, LOE: B) <120 min when the pt presents to hospital without PCI capability (Class I, LOE: B) 2011 Guidelines Indications

Transfer, Facilitated and Rescue PCI Primary PCI is preferred for STEMI Primary PCI preferred if transfer times are short Pharmacoinvasive strategy is preferred for when transfer times are long Early “routine” PCI after lysis is preferred over rescue strategy (particularly in high risk pts) Includes rescue PCI for failed reperfusion Prevents early reocclusion after successful lysis Primary PCI is preferred for STEMI Primary PCI preferred if transfer times are short Pharmacoinvasive strategy is preferred for when transfer times are long Early “routine” PCI after lysis is preferred over rescue strategy (particularly in high risk pts) Includes rescue PCI for failed reperfusion Prevents early reocclusion after successful lysis Summary

Extent of salvage (% of area at risk) Treatment objectives Time to treatment is critical Opening the IRA (PCI > lysis) Hours Relationship Between Myocardial Salvage and Survival Gersh, Stone, Holmes. JAMA 2005 Median U.S. Sx-ER: 2° Mortality reduction (%) 90’ DBT Goal U.S. PCI Sx-bal: 3.5° Modifying factors CollateralsIschemic preconditioning Collaterals Ischemic preconditioning MVO 2

2012: Do whatever it takes to reduce time from symptom onset to ER arrival and time from ER arrival to PCI!  Public awareness of MI Sx Chest pain centers of excellence with lower DBTs and excellent outcomes Regional coordination Ambulance ECG telemetry Ambulance/ER CCL activation ICs sleep in hospital Continual QI

Extent of salvage (% of area at risk) Treatment objectives Time to treatment is critical Opening the IRA (PCI > lysis) Hours Relationship Between Myocardial Salvage and Survival Gersh, Stone, Holmes. JAMA 2005 Median U.S. Sx-ER: 1.75° Modifying factors CollateralsIschemic preconditioning Collaterals Ischemic preconditioning MVO 2 Mortality reduction (%) Goal U.S. PCI Sx-bal: 2.75° 60’ DBT

Krumholz H M et al. Circulation 2011;124: % 91.4% Median 96 mins Median 64 mins Door-to-balloon time <90 mins at CMS hospitals N pts48,97752,02851,29853,03253,68242,150

Extent of salvage (% of area at risk) Treatment objectives Time to treatment is critical Opening the IRA (PCI > lysis) Hours Relationship Between Myocardial Salvage and Survival Gersh, Stone, Holmes. JAMA 2005 Mortality reduction (%) Median U.S. Sx-ER: 1.5° 45’ DBT Goal U.S. PCI Sx-bal: 2.25° Modifying factors CollateralsIschemic preconditioning Collaterals Ischemic preconditioning MVO 2

Extent of salvage (% of area at risk) Treatment objectives Time to treatment is critical Opening the IRA (PCI > lysis) Hours Relationship Between Myocardial Salvage and Survival: The future? Mortality reduction (%) Median U.S. Sx-ER: 1.5° Goal U.S. PCI Sx-bal: 2.25° 45’ DBT Modifying factors Collaterals Collaterals Ischemic preconditioning Ischemic preconditioning MVO 2 Change the shape of the curve! Interventions to improve: Reperfusion injury Microcirculatory function Microcirculatory function

p=0.01 Interhospital Delay in Transfer Door-to-Door Times 1 year Mortality (n=616 pts) % De Luca G: AJC 2005; 95: 1361

p=0.01 Interhospital Delay in Transfer Door-to-Door Times 1 year Mortality (n=616 pts) % De Luca G: AJC 2005; 95: 1361

US Transfer Delay for Primary PCI (NRMI 3 / 4) % Nallamothu B: Circulation 2005; 111: 761 Total Door to Balloon Time (h) <16% < 2h52% > 3h

Reperfusion Options for Transfer Patients with Expected Delays Lysis; ischemia-guided transfer for rescue PCI Lysis, routine transfer for aggressive rescue PCI Primary PCI (no matter how long it takes) Lysis with transfer for immediate (“early” PCI): Pharmaco-invasive strategy Lysis; ischemia-guided transfer for rescue PCI Lysis, routine transfer for aggressive rescue PCI Primary PCI (no matter how long it takes) Lysis with transfer for immediate (“early” PCI): Pharmaco-invasive strategy

7 RCT; n=2961 pts

AMICO: Alliance for Myocardial Infarction Care Optimization Raymond G. McKay, MD Ali. E. Denktas, MD, Haris Athar, MD, Stefano Sdringola, MD, H. Vernon Anderson, MD, Richard W. Smalling, MD, PhD Timothy D. Henry, MD, David M. Larson, MD Michael Simons, MD, Nathaniel W. Niles, MD Holger Thiele, MD Gerhard Schuler, MD Chul Ahn, PhD

Days from Randomization % Standard (n=496) Pharmacoinvasive (n=508) Primary Endpoint: 30-Day Death, re-MI, CHF, Severe Recurrent Ischemia, Shock OR=0.54 (0.37, 0.78) p= N=1,004 pts

Days from Randomization % Standard (n=496) Pharmacoinvasive (n=508) n=496 n= Primary Endpoint: 30-Day Death, re-MI, CHF, Severe Recurrent Ischemia, Shock OR=0.54 (0.37, 0.78) p= N=1,004 pts